NEW YORK – (BUSINESS WIRE) – Sep 23, 2021–
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial medical technology company and its majority-owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), announced yesterday that Lucid has publicly filed a statement of ‘registration on Form S-1 with the United States Securities and Exchange Commission (the “SEC”) regarding the proposed initial public offering of its common shares. The number of shares to be offered and the price range of the offer have not yet been determined. Lucid Diagnostics intends to list its common shares on the Nasdaq Stock Market under the symbol “LUCD”.
Cantor Fitzgerald & Co. and Canaccord Genuity LLC will act as co-book managers for the proposed offering. BTIG, LLC and Needham & Co., LLC will act as co-leads of the proposed offering.
The offer will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from any of the following organizations:
Cantor Fitzgerald & Co., Attention: Capital Markets Department
Canaccord Genuity LLC, Attention: Union Service
A registration statement on Form S-1 relating to the proposed sale of these securities has been filed with the SEC but has not yet come into effect. These securities may not be sold, nor offers to purchase may be accepted, before the entry into force of the registration statement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. before registration or qualification. under the securities laws of any such state or jurisdiction.
PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diverse product portfolio addressing unmet clinical needs encompassing a wide range of clinical areas with attractive regulatory pathways and market opportunities. Its principal subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for the widespread early detection of precancer and esophageal cancer – the EsoGuard ® Esophageal DNA Test and the EsoCheck ® Esophageal Cell Collection Device. . Its GI Health division also includes the complementary esophageal ablation device EsoCure ™ with Caldus ™ technology. Another major subsidiary, Veris Health Inc., is a digital health company developing the world’s first smart implantable vascular access port with biological sensors and wireless communication to improve personalized cancer care through remote patient monitoring. . Its Minimally Invasive Interventions division markets its CarpX ® minimally invasive device for carpal tunnel syndrome. Other divisions include Infusion Therapy (PortIO ™ implantable intraosseous vascular access device and NextFlo ™ intravenous infusion kit) and Emerging Innovations (non-invasive laser blood glucose monitoring, pediatric ear tubes and mechanical circulatory support).
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These forward-looking statements, based on the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from forward-looking statements. The risks and uncertainties that may cause such differences include, among others, the ability to complete the initial public offering of Lucid; the volatility of the price of PAVmed common shares, Series W warrants and Series Z warrants; general economic and market conditions; uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design and results of the preclinical studies of PAVmed; if and when PAVmed’s products are authorized by regulatory authorities; market acceptance of PAVmed products once authorized and marketed; our ability to raise additional funds and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company is monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effects on the Company’s financial and operating results, to be dictated, among other things, by the success of efforts to contain it and the impact of the measures taken in response. New risks and uncertainties can arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond the control of PAVmed. For a further list and description of these important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Article IA, “Risk Factors”, in PAVmed’s most recent annual report on Form 10- K filed with the Securities and Exchange Commission as it may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent annual report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in the events, conditions or circumstances on which such expectations may be based, or which may affect the likelihood that actual results differ from those contained in forward-looking statements.
Katie Gallagher / Kristi Bruno
(617) 792-3937 / (617) 865-3940
KEYWORD: NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH MEDICAL SUPPLIES ONCOLOGY
Copyright Business Wire 2021.
PUB: 09/23/2021 9:30 a.m. / DISC: 09/23/2021 9:34 a.m.
Copyright Business Wire 2021.